Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Janux Therapeutics Inc. (the “Company”) for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. § 1350, that to his knowledge:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | | |
Date: March 10, 2023 | | By: | /s/ David Campbell, Ph.D. |
| | | David Campbell, Ph.D. |
| | | President and Chief Executive Officer (Principal Executive Officer) |
| | | |
Date: March 10, 2023 | | By: | /s/ Tighe Reardon |
| | | Tighe Reardon |
| | | Acting Chief Financial Officer (Principal Financial and Accounting Officer) |
